Menu
Menu
| Product | Indication | Discovery | Preclinicals | Clinical Trials | Approval | Launched |
|---|---|---|---|---|---|---|
| INSULIN ASPART 100 IU/ML (Biosimilar to: Novorapid®) | Rapid acting insulin analogue for treatment of type 1 & 2 diabetes mellitus | |||||
| INSULIN ASPART MIX 100 IU/ML (Biosimilar to: Novomix®) | Combination of rapid acting insulin and an intermediate acting type insulin for treatment of type 1&2 diabetes mellitus | |||||
| INSULIN GLARGINE 100 IU/ML (Biosimilar to: Lantus®) | Long acting Insulin glargine for treatment of type 1 & 2 diabetes mellitus | |||||
| INSULIN LISPRO (Biosimilar to: Humalog®) | Rapid acting insulin analog for the treatment of type 1& type 2 diabetes mellitus | |||||
| INSULIN DEGLUDEC (Biosimilar to: Tresiba®) | Ultra long acting insulin for the treatment of type 1 & type 2 diabetes mellitus | |||||
| INSULIN DEGLUDEC+ASPART (Biosimilar to : Ryzodeg®) | Dual insulin combination to manage diabetes by keeping blood sugar in tye 1 & 2 diabetes mellitus | |||||
| INSULIN ASPART PUMP (Reference product : Undisclosed) | Insulin aspart pump delivers tiny amounts of insulin every few minutes | |||||
| LIRAGLUTIDE (Biosimilar to: Victoza®) | GLP -1 Reduce risk of cardiovascular events in Type 2 diabetes mellitus patients | |||||
| LIRAGLUTIDE +ASPART (Reference product : Undisclosed) | GLP & rapid acting insulin for treating type 1 and 2, also reduce risk of cardiovascular events in type 2 diabetes mellitus and | |||||
| BGN-26 (DIABETIC FOOT ULCER) (Reference product : Undisclosed) | Ointment for diabetic foot ulcers | |||||
| TIRZEPATIDE (Reference to : Mounjaro®) | Dual agonist for GLP and GIP peptide for treatment of type 2 diabetes mellitus | |||||
| EXENITIDE (Reference to : Byetta®) | GLP-1 Analog for treatment of type 2 diabetes mellitus | |||||
| LIRAGLUTIDE+DEGLUDEC (Reference to : Xultophy®) | GLP-1 and long acting insulin for the treatment of type 2 diabetes mellitus | |||||
| GLARGINE 300 IU/ML (Biosimilar to : Toujeo®) | Long acting Insulin glargine for treatment of type 1 & 2 diabetes mellitus | |||||
| INSULIN GLARGINE +LIXISENATIDE (Reference to : Soliqua®) | Long acting GLP-1 agonist for the treatment of adult patients for type 2 diabetes | |||||
| Pembrolizumab(Biosimilar to: Keytruda®) | Anti PD-1 Pathway for cancer treatment | |||||
| NIVELUMAB (Biosimilar to: Opdiva®) | To treat melanoma and other cancers | |||||
©2021, All rights reserved, BioGenomics Limited.
Designed & Developed by W